Company research
PSYENCE BIOMEDICAL LTD.
CIK 1985062Updated Sep 26, 2026
PBM price & chart
Loading TradingView…
NASDAQ:PBM on TradingView ↗About the company
Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | 1,011,790Source | -51,159,048Source |
| Additional Financial Items | ||
| AdjustmentsForSharebasedPaymentsUSD | — | 317,882Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -9,860Source | 3,658Source |
| GeneralAndAdministrativeExpenseUSD | 1,209,847Source | 557,904Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 1,000,000Source | — |
| ProceedsFromIssuingSharesUSD | 1,742,051Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | 150,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Additional Financial Items | ||
| BasicEarningsLossPerShareUSD per share | 5.24Source | -7.82Source |
| DilutedEarningsLossPerShareUSD per share | 5.24Source | -7.82Source |
| FinanceCostsUSD | — | 52,941Source |
| FinanceIncomeUSD | — | -2,134Source |
| GeneralAndAdministrativeExpenseUSD | 1,209,847Source | 557,904Source |
| InterestExpenseUSD | 9,270Source | — |
| OtherIncomeUSD | — | -879,344Source |
| ProfessionalFeesExpenseUSD | 1,623,209Source | 1,158,484Source |
| ProfitLossBeforeTaxUSD | -3,658,754Source | — |
| ResearchAndDevelopmentExpenseUSD | 342,168Source | 954,593Source |
| RevenueFromInterestUSD | 95,787Source | — |
Filing attachments
ea030630801ex99-1.htm · 6-K · 2026-09-23
Exhibit 99.1 PSYENCE BIOMEDICAL LTD. NASDAQ: PBM FOR IMMEDIATE RELEASE Psyence BioMed Announces Strategic Ibogaine Investment Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has bee…
Read attachment ↗